DrugPatentWatch Database Preview
Patent: 10,052,307
Try a free trial
See Plans and Pricing
Summary for Patent: 10,052,307
| Title: | Micellar nanocomplex |
| Abstract: | The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system. |
| Inventor(s): | Kurisawa; Motoichi (Singapore, SG), Nunnarpas; Yongvongsoontorn (Singapore, SG), Ying; Jackie Y (Singapore, SG), Chung; Joo Eun (Singapore, SG), Bae; Ki Hyun (Singspore, SG), Tan; Min-han (Singapore, SG), Lee; Esther (Singapore, SG) |
| Assignee: | Agency for Science, Technology and Research (Singapore, SG) |
| Application Number: | 15/309,675 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,052,307
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | LUCENTIS | ranibizumab | INJECTABLE; INJECTION | 125156 | 001 | 2006-06-30 | ➤ Sign Up | Agency for Science, Technology and Research (Singapore, SG) | 2034-05-09 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 003 | 2006-09-27 | ➤ Sign Up | Agency for Science, Technology and Research (Singapore, SG) | 2034-05-09 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 002 | 2006-09-27 | ➤ Sign Up | Agency for Science, Technology and Research (Singapore, SG) | 2034-05-09 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | ➤ Sign Up | Agency for Science, Technology and Research (Singapore, SG) | 2034-05-09 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | ➤ Sign Up | Agency for Science, Technology and Research (Singapore, SG) | 2034-05-09 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | ➤ Sign Up | Agency for Science, Technology and Research (Singapore, SG) | 2034-05-09 | RX | search | |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | ➤ Sign Up | Agency for Science, Technology and Research (Singapore, SG) | 2034-05-09 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,052,307
| Country | Patent Number | Publication Date |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015171079 | Nov 12, 2015 |
| United States of America | 2017258926 | Sep 14, 2017 |
| United States of America | 2019008830 | Jan 10, 2019 |
| Singapore | 11201609333Y | Dec 29, 2016 |
| Mexico | 2016014606 | Aug 24, 2017 |
| South Korea | 20170007780 | Jan 20, 2017 |
| Japan | 2017518280 | Jul 06, 2017 |
| >Country | >Patent Number | >Publication Date |
